BioCentury | Jun 21, 2019
Finance

What Australian biotech needs to compete globally

...an Australian entrepreneur who previously founded companies including Fibrotech Therapeutics Pty. Ltd., “Trying to raise $7 million for Fibrotech...
...The system is so different now, but there’s still a ways to go,” he said. Fibrotech...
BioCentury | Apr 27, 2015
Finance

Big cash down under

...round (see BioCentury, April 14, 2014) . The firm's most recent exit was fibrosis play Fibrotech Therapeutics Pty. Ltd....
BioCentury | Oct 25, 2014
Top Story

Shire sets its peer group

...of orphan disease company Lumena Pharmaceuticals Inc. and a $75 million buyout of renal specialist Fibrotech Therapeutics Pty. Ltd....
BioCentury | Jun 16, 2014
Finance

Shire shopping

...Lumena Pharmaceuticals Inc. for $260 million in cash up front, and rare kidney disease company Fibrotech Therapeutics Pty. Ltd....
BioCentury | May 5, 2014
Company News

Fibrotech, Shire deal

...Shire will acquire fibrosis play Fibrotech for $75 million up front, plus undisclosed milestones. Fibrotech's FT011...
...disease that affects the kidney's filtering system and causes serious fibrosis. Shire would also gain Fibrotech's...
...approval by Australia's Foreign Investment Review Board, which Fibrotech expects to take between 30-60 days. Fibrotech Therapeutics Pty. Ltd....
BioCentury | May 2, 2014
Financial News

Shire reports 1Q14 earnings, raises guidance

...will acquire fibrosis play Fibrotech Therapeutics Pty. Ltd. (Melbourne, Australia) for $75 million up front, plus undisclosed milestones. Fibrotech's...
BioCentury | Mar 17, 2014
Clinical News

FT011: Phase Ia data

...nephropathy associated with Type I or II diabetes is expected to be completed in June. Fibrotech Therapeutics Pty. Ltd....
Items per page:
1 - 7 of 7
BioCentury | Jun 21, 2019
Finance

What Australian biotech needs to compete globally

...an Australian entrepreneur who previously founded companies including Fibrotech Therapeutics Pty. Ltd., “Trying to raise $7 million for Fibrotech...
...The system is so different now, but there’s still a ways to go,” he said. Fibrotech...
BioCentury | Apr 27, 2015
Finance

Big cash down under

...round (see BioCentury, April 14, 2014) . The firm's most recent exit was fibrosis play Fibrotech Therapeutics Pty. Ltd....
BioCentury | Oct 25, 2014
Top Story

Shire sets its peer group

...of orphan disease company Lumena Pharmaceuticals Inc. and a $75 million buyout of renal specialist Fibrotech Therapeutics Pty. Ltd....
BioCentury | Jun 16, 2014
Finance

Shire shopping

...Lumena Pharmaceuticals Inc. for $260 million in cash up front, and rare kidney disease company Fibrotech Therapeutics Pty. Ltd....
BioCentury | May 5, 2014
Company News

Fibrotech, Shire deal

...Shire will acquire fibrosis play Fibrotech for $75 million up front, plus undisclosed milestones. Fibrotech's FT011...
...disease that affects the kidney's filtering system and causes serious fibrosis. Shire would also gain Fibrotech's...
...approval by Australia's Foreign Investment Review Board, which Fibrotech expects to take between 30-60 days. Fibrotech Therapeutics Pty. Ltd....
BioCentury | May 2, 2014
Financial News

Shire reports 1Q14 earnings, raises guidance

...will acquire fibrosis play Fibrotech Therapeutics Pty. Ltd. (Melbourne, Australia) for $75 million up front, plus undisclosed milestones. Fibrotech's...
BioCentury | Mar 17, 2014
Clinical News

FT011: Phase Ia data

...nephropathy associated with Type I or II diabetes is expected to be completed in June. Fibrotech Therapeutics Pty. Ltd....
Items per page:
1 - 7 of 7